Online inquiry

IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14147MR)

This product GTTS-WQ14147MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14147MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ457MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ15886MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ15487MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ11222MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ11616MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ3666MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ1856MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ1238MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW